GlobalData
Shaping AML treatment: how menin inhibitors are changing the game
The menin inhibitors revumenib and ziftomenib are in close competition for a share of the acute myeloid leukaemia (AML) market.

The menin inhibitors revumenib and ziftomenib are in close competition for a share of the acute myeloid leukaemia (AML) market.